All In MedTech

Device Trial Radar · NCT05443451

BETTY: BEnign Prostatic Hyperplasia Transperineal Targeted Microwave therapY

3D-Ultrasound-Guided Transperineal Microwave Needle Ablation for Men With Symptomatic Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Sep 8, 2022

Primary completion

Oct 5, 2023

Study completion Oct 30, 2023

Sponsor

Lead sponsor
Chinese University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Koelis
First posted
Jul 5, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pilot study on applying 3D-Ultrasound-Guided Transperineal Microwave needle ablation for men with symptomatic benign prostatic hyperplasia (BPH).

Conditions

  • Prostate Hyperplasia

Interventions

  • 3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPHDevice

    The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AE) and serious adverse events (SAE) related to the treatmentTime frame: At 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Prince of Wales Hospital

    Hong Kong, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.